Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › B-cell Malignancies

B-cell Malignancies

Part of Cancer

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for B-cell Malignancies

5 trials tracked for B-cell Malignancies.

5Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 4 Phase 1 1
  1. Phase 2 A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) Completed
  2. Phase 2 A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) Completed
  3. Phase 2 A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies Completed
  4. Phase 2 Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies Completed
  5. Phase 1 Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies Completed

Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Narrative review suggests idiotype-directed CAAR-T therapy remains hypothetical for B-cell malignancies
Hematology Sys. Review
Narrative review suggests idiotype-directed CAAR-T therapy remains hypothetical for B-cell malignancies Idiotype-directed CAAR-T therapy remains a hypothesis for B-cell malignancies
This narrative review discusses idiotype-directed CAAR-T therapy for B-cell malignancies including chronic lymphocytic leukemia and indolent…
A narrative review suggests idiotype-directed CAAR-T therapy is a theoretical option for B-cell cancers, not a current treatment.
Frontiers May 23, 2026
Review of CAR-T cell therapy for pancreatic ductal adenocarcinoma reports no specific outcomes or safety data
Allergy & Immunology Sys. Review
Review of CAR-T cell therapy for pancreatic ductal adenocarcinoma reports no specific outcomes or safety data First CAR-T for Pancreatic Cancer Approved
This narrative review addresses the application of CAR-T cell therapy for pancreatic ductal adenocarcinoma.
For the first time, a new drug approved for pancreatic cancer uses immune cells to attack solid tumors instead of just blood cancers.
Frontiers Apr 15, 2026
Phase 2 Study of BGB-16673 in B-Cell Malignancies: Safety and Dose Findings
Hematology Phase II
Phase 2 Study of BGB-16673 in B-Cell Malignancies: Safety and Dose Findings Could This New Drug Offer Hope for Patients with Tough Blood Cancers?
This ongoing Phase 1/2 trial evaluates BGB-16673 in B-cell malignancies, focusing on safety and dose determination. Primary outcomes include…
Patients with tough B-cell blood cancers may find a new option in the drug BGB-16673, currently being tested to find the right safe dose and…
CT.gov Mar 27, 2026

Questions about B-cell Malignancies

Does the review mention any specific outcomes for pancreatic cancer CAR-T therapy?

Reviews indicate that while CAR-T therapy is established for B-cell malignancies, there are currently no specific outcomes or safety data available for its use in pancreatic cancer.

Full answer →
What safety data exists for CAR-T cell therapy in B-cell malignancies?

CAR-T therapy for B-cell malignancies has transformed treatment but carries risks like B-cell aplasia and cytokine release syndrome. New approaches aim to improve safety while maintaining effectiveness.

Full answer →